Whalen Wealth Management Inc. Has $1.64 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Whalen Wealth Management Inc. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 268.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,389 shares of the medical research company’s stock after purchasing an additional 2,469 shares during the period. Thermo Fisher Scientific accounts for approximately 1.0% of Whalen Wealth Management Inc.’s investment portfolio, making the stock its 24th biggest holding. Whalen Wealth Management Inc.’s holdings in Thermo Fisher Scientific were worth $1,644,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Pacifica Partners Inc. increased its position in Thermo Fisher Scientific by 3,181.4% during the third quarter. Pacifica Partners Inc. now owns 5,119 shares of the medical research company’s stock worth $2,717,000 after acquiring an additional 4,963 shares during the period. Talbot Financial LLC boosted its stake in shares of Thermo Fisher Scientific by 7.7% in the third quarter. Talbot Financial LLC now owns 26,387 shares of the medical research company’s stock valued at $12,798,000 after buying an additional 1,888 shares during the period. Genesis Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at $227,000. First County Bank CT raised its stake in Thermo Fisher Scientific by 4.8% in the third quarter. First County Bank CT now owns 1,447 shares of the medical research company’s stock valued at $702,000 after purchasing an additional 66 shares in the last quarter. Finally, Hilltop National Bank grew its stake in Thermo Fisher Scientific by 28.4% during the third quarter. Hilltop National Bank now owns 1,075 shares of the medical research company’s stock worth $521,000 after buying an additional 238 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TMO. Wells Fargo & Company upped their price target on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a report on Monday. Morgan Stanley upped their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. UBS Group lifted their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $616.60.

Thermo Fisher Scientific Stock Down 0.1%

Thermo Fisher Scientific stock opened at $562.13 on Friday. The firm has a market cap of $211.20 billion, a price-to-earnings ratio of 32.47, a PEG ratio of 4.17 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm has a 50 day moving average price of $568.17 and a two-hundred day moving average price of $495.54.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock repurchase plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the sale, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. The trade was a 36.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michel Lagarde sold 22,046 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total value of $12,424,243.76. Following the transaction, the chief operating officer owned 84,117 shares in the company, valued at $47,404,976.52. The trade was a 20.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 149,271 shares of company stock valued at $86,507,282 over the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.